Tumor-stromal cell interactions and opportunities for therapeutic intervention

Current Opinion in Pharmacology

Volumn 10, Issue 4, 2010, Pages 369-374

  Udagawa, Taturo ^a   Wood, Mark ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTARABINE; CYTOTOXIC AGENT; IMATINIB; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE B; RANTES; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL INTERACTION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SCREENING; ENDOTHELIUM CELL; FIBROBLAST; GASTROINTESTINAL STROMAL TUMOR; HEMATOPOIETIC CELL; HUMAN; HYPOXIA; INNATE IMMUNITY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESENCHYME CELL; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; STROMA CELL; SURVIVAL RATE; TUMOR;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL COMMUNICATION; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; PYRIDINES; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 77955274176     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.06.010     Document Type: Review

References (59)

1. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
2. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
3. De Palma M., Venneri M.A., Galli R., Sergi L.S., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
4. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
5. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
6. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13:31-36.
7. Loeffler M., Kruger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006, 116:1955-1962.
8. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., Akiyama T., Kuroda H., Kawano Y., Kobune M., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
9. Kim D.W., Huamani J., Fu A., Hallahan D.E. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 2006, 64:38-46.
10. Shain K.H., Yarde D.N., Meads M.B., Huang M., Jove R., Hazlehurst L.A., Dalton W.S. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009, 69:1009-1015.
11. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
12. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
13. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
14. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896.
15. Shinohara E.T., Maity A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Curr Mol Med 2009, 9:1034-1045.
16. Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D.V., Lahdenranta J., Chung D.C., Fischman A.J., Lauwers G.Y., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
17. Nieder C., Wiedenmann N., Andratschke N.H., Astner S.T., Molls M. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2007, 2:163-168.
18. O'Connor P.M., Lapointe T.K., Beck P.L., Buret A.G. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis 2010, (12 February 2010) [Epub ahead of print].
19. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
20. Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat Rev Cancer 2003, 3:276-285.
21. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201.
22. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
23. Purhonen S., Palm J., Rossi D., Kaskenpaa N., Rajantie I., Yla-Herttuala S., Alitalo K., Weissman I.L., Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 2008, 105:6620-6625.
24. Wickersheim A., Kerber M., de Miguel L.S., Plate K.H., Machein M.R. Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer 2009, 125:1771-1777.
25. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., Antin J.H., Myerson D., Hamilton S.R., Vogelstein B., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005, 11:261-262.
26. Koga M., Kai H., Egami K., Murohara T., Ikeda A., Yasuoka S., Egashira K., Matsuishi T., Kai M., Kataoka Y., et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008, 365:279-284.
27. De Palma M., Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy?. Biochim Biophys Acta 2009, 1796:5-10.
28. Paunescu V., Bojin F.M., Tatu C.A., Gavriliuc O.I., Rosca A., Gruia A.T., Tanasie G., Bunu C., Crisnic D., Gherghiceanu M., et al. Tumor-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med 2010, (24 February 2010) [Epub ahead of print].
29. van Zijl F., Mair M., Csiszar A., Schneller D., Zulehner G., Huber H., Eferl R., Beug H., Dolznig H., Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009, 28:4022-4033.
30. Konings I.R., Verweij J., Wiemer E.A., Sleijfer S. The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 2009, 9:439-450.
31. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
32. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
33. Christov C., Chretien F., Abou-Khalil R., Bassez G., Vallet G., Authier F.J., Bassaglia Y., Shinin V., Tajbakhsh S., Chazaud B., Gherardi R.K. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol Biol Cell 2007, 18:1397-1409.
34. Palmer T.D., Willhoite A.R., Gage F.H. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000, 425:479-494.
35. Li B., Bailey A.S., Jiang S., Liu B., Goldman D.C., Fleming W.H. Endothelial cells mediate the regeneration of hematopoietic stem cells. Stem Cell Res 2010, 4:17-24.
36. Sneddon J.B. The contribution of niche-derived factors to the regulation of cancer cells. Methods Mol Biol 2009, 568:217-232.
37. Reya T., Morrison S.J., Clarke I.D., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
38. Veeravagu A., Bababeygy S.R., Kalani M.S., Hou L., Tse V. The cancer stem cell-vascular niche complex in brain tumor formation. Stem Cells Dev 2008, 17:859-867.
39. Demicheli R., Retsky M.W., Swartzendruber D.E., Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997, 8:1075-1080.
40. Folkman J., Kalluri R. Cancer without disease. Nature 2004, 427:787.
41. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
42. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
43. Keating G.M., Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009, 69:223-240.
44. Kerbel R.S., Viloria-Petit A., Klement G., Rak J. 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000, 36:1248-1257.
45. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
46. Browder T., Butterfield C.E., Kräling B.M., Shi B., Marshall B., O'Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
47. Ruan J., Martin P., Coleman M., Furman R.R., Cheung K., Faye A., Elstrom R., Lachs M., Hajjar K.A., Leonard J.P. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010, 116:2655-2664.
48. Calvani N., Orlando L., Nacci A., Sponziello F., Cinefra M., Cinieri S. Metronomic chemotherapy against cancer: from paradigm to clinical practice?. Tumori 2009, 95:843-845.
49. Italiano A., Toulmonde M., Lortal B., Stoeckle E., Garbay D., Kantor G., Kind M., Coindre J.M., Bui B. " Metronomic" chemotherapy in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 2010, 66:197-202.
50. Samuel D.P., Wen P.Y., Kieran M.W. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs 2009, 18:973-983.
51. Fuchs D., Rodriguez A., Eriksson S., Christofferson R., Sundberg C., Azarbayjani F. Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Int J Cancer 2010, 126:2773-2789.
52. Khosravi Shahi P., Soria Lovelle A., Perez Manga G. Tumoral angiogenesis and breast cancer. Clin Transl Oncol 2009, 11:138-142.
53. Folkman J. Tumor angiogenesis. N Engl J Med 1971, 285:1182-1186.
54. Clark J.W., Eder J.P., Ryan D., Lathia C., Lenz H.J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005, 11:5472-5480.
55. Timke C., Zieher H., Roth A., Hauser K., Lipson K.E., Weber K.J., Debus J., Abdollahi A., Huber P.E. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008, 14:2210-2219.
56. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
57. Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115:3618-3630.
58. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
59. Xiang R., Luo Y., Niethammer A.G., Reisfeld R.A. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 2008, 222:117-128.